The search textbox has an autosuggest feature. When you enter three or more characters,
a list of up to 10 suggestions will popup under the textbox. Use the arrow keys
to move through the suggestions. To select a suggestion, hit the enter key. Using
the escape key closes the listbox and puts you back at the textbox. The radio buttons
allow you to toggle between having all search items start with or contain the text
you entered in the search box.
caricotamide/tretazicar
A combination therapy consisting of the prodrug tretazicar and the enzyme co-substrate caricotamide with potential antineoplastic activity. In the presence of separately and simultaneously administered caricotamide, tretazicar is converted to the short-lived cytotoxic DNA cross-linking agent dinitrobenzamide by NAD(P)H quinine oxidoreductase 2 (NQO2), resulting in the inhibition of DNA replication and the induction of apoptosis. NQO2 has been found to be elevated in certain cancers such as hepatocellular carcinoma (HCC). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| US brand name: | | Prolarix | |
| |||
| Code name: | | EP-0152R/CB1954 | |
| |||
| Chemical structure: | | 1-carbamoylmethyl-3-carbamoyl-1,4-dihydropyridine/5-(aziridin-1-yl)-2,4-dinitrobenzamide | |
| |||
